Unlocking the broader value of biologic therapies through biosimilar-enabled access and repositioning

Mikel Berdud, Paul Oyalo, Libby Tungate, Lou Garrison and Amanda Cole

Contract Research from Office of Health Economics

Abstract: Biologic medicines account for over 40% of global pharmaceutical spend. When originator patents expire, biosimilar competition should drive prices down, generating cost-savings, broadening access, and improving outcomes, yet that promise remains largely unrealised. From the first US launch in 2015 up to 2025, biosimilars saved the US health system an estimated $56.2 billion in drug costs, but one analysis estimates that $124.5 billion in savings could be achieved: a $68 billion gap. Supply- and demand-side barriers as well as contracting structures produce low penetration, recurring shortage risk, and a growing ‘biosimilar void’. The dominant policy response has been narrow, focusing…

JEL-codes: I1 (search for similar items in EconPapers)
Date: 2026-09-23
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.ohe.org/publications/unlocking-the-bro ... s-and-repositioning/ (text/html)
https://www.ohe.org/wp-content/uploads/2026/09/Unl ... d-repositioning-.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ohe:conres:002537

Access Statistics for this paper

More papers in Contract Research from Office of Health Economics Contact information at EDIRC.
Bibliographic data for series maintained by Publications Manager ( this e-mail address is bad, please contact ).